JP2012530705A5 - - Google Patents

Download PDF

Info

Publication number
JP2012530705A5
JP2012530705A5 JP2012516178A JP2012516178A JP2012530705A5 JP 2012530705 A5 JP2012530705 A5 JP 2012530705A5 JP 2012516178 A JP2012516178 A JP 2012516178A JP 2012516178 A JP2012516178 A JP 2012516178A JP 2012530705 A5 JP2012530705 A5 JP 2012530705A5
Authority
JP
Japan
Prior art keywords
methyl
pharmaceutically acceptable
acceptable salt
trifluoromethyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012516178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012530705A (ja
JP5596139B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/038568 external-priority patent/WO2010147917A1/en
Publication of JP2012530705A publication Critical patent/JP2012530705A/ja
Publication of JP2012530705A5 publication Critical patent/JP2012530705A5/ja
Application granted granted Critical
Publication of JP5596139B2 publication Critical patent/JP5596139B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012516178A 2009-06-19 2010-06-15 二置換フタラジンヘッジホッグ経路アンタゴニスト Active JP5596139B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21862809P 2009-06-19 2009-06-19
US61/218,628 2009-06-19
PCT/US2010/038568 WO2010147917A1 (en) 2009-06-19 2010-06-15 Disubstituted phthalazine hedgehog pathway antagonists

Publications (3)

Publication Number Publication Date
JP2012530705A JP2012530705A (ja) 2012-12-06
JP2012530705A5 true JP2012530705A5 (cg-RX-API-DMAC7.html) 2014-07-17
JP5596139B2 JP5596139B2 (ja) 2014-09-24

Family

ID=42332981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012516178A Active JP5596139B2 (ja) 2009-06-19 2010-06-15 二置換フタラジンヘッジホッグ経路アンタゴニスト

Country Status (35)

Country Link
US (2) US8273742B2 (cg-RX-API-DMAC7.html)
EP (1) EP2443104B1 (cg-RX-API-DMAC7.html)
JP (1) JP5596139B2 (cg-RX-API-DMAC7.html)
KR (1) KR101389165B1 (cg-RX-API-DMAC7.html)
CN (1) CN102459233B (cg-RX-API-DMAC7.html)
AR (1) AR077014A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010260244B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1011601A2 (cg-RX-API-DMAC7.html)
CA (1) CA2764542C (cg-RX-API-DMAC7.html)
CL (1) CL2011003147A1 (cg-RX-API-DMAC7.html)
CO (1) CO6480932A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110658A (cg-RX-API-DMAC7.html)
DK (1) DK2443104T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2011000386A (cg-RX-API-DMAC7.html)
EA (1) EA019059B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011541A (cg-RX-API-DMAC7.html)
ES (1) ES2409054T3 (cg-RX-API-DMAC7.html)
HN (1) HN2011003139A (cg-RX-API-DMAC7.html)
HR (1) HRP20130408T1 (cg-RX-API-DMAC7.html)
IL (1) IL216599A (cg-RX-API-DMAC7.html)
JO (1) JO2931B1 (cg-RX-API-DMAC7.html)
MA (1) MA33363B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011014029A (cg-RX-API-DMAC7.html)
MY (1) MY156667A (cg-RX-API-DMAC7.html)
NZ (1) NZ596882A (cg-RX-API-DMAC7.html)
PE (1) PE20121050A1 (cg-RX-API-DMAC7.html)
PL (1) PL2443104T3 (cg-RX-API-DMAC7.html)
PT (1) PT2443104E (cg-RX-API-DMAC7.html)
SG (1) SG177289A1 (cg-RX-API-DMAC7.html)
SI (1) SI2443104T1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000627A1 (cg-RX-API-DMAC7.html)
TW (1) TWI385165B (cg-RX-API-DMAC7.html)
UA (1) UA106755C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010147917A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201108587B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102066353B (zh) * 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
MX2011004683A (es) * 2008-11-03 2011-06-20 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida.
MX2011005176A (es) * 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
BRPI0921782A2 (pt) 2008-11-17 2019-09-24 Lilly Co Eli antagonistas da via hedgehog de piridazina tetrassubstituída
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
AU2012232670A1 (en) 2011-03-23 2013-09-12 Ariel-University Research And Development Company Ltd. Treatment of proliferative disorders with a chemiluminescent agent
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
CN105017140B (zh) * 2014-04-28 2017-12-29 复旦大学 邻氨基苯甲酰胺化合物及其制备方法和用途
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
MX387917B (es) 2015-06-04 2025-03-19 Pellepharm Inc Formulaciones topicas para suministrar compuestos inhibidores de hedgehog y uso de los mismos.
EP3303289A4 (en) * 2015-06-05 2018-11-14 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
CA3017411C (en) 2016-03-15 2024-06-25 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for use in the treatment of solid tumors
CN106279114B (zh) * 2016-08-04 2019-01-29 东南大学 一种Taladegib的合成方法
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
CN106831718B (zh) * 2016-12-30 2019-05-07 上海科技大学 平滑受体配体及其应用
JP7323457B2 (ja) 2017-05-18 2023-08-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 肥満細胞疾患の処置のための方法及び医薬組成物
EP4173639A4 (en) 2020-06-26 2024-03-13 RaQualia Pharma Inc. Method for selecting cancer patient for which combination therapy of retinoid and cancer treatment agent will be effective, and combined drug of retinoid and cancer treatment agent
CN116349204A (zh) 2020-10-13 2023-06-27 奋进生物医药公司 治疗纤维化的方法
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function
WO2025189041A1 (en) * 2024-03-07 2025-09-12 Endeavor Biomedicines, Inc. Methods of treating fibrosis
WO2025242197A1 (zh) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 氘代的Hedgehog通路SMO受体抑制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (cg-RX-API-DMAC7.html) 1977-06-03 1981-03-07 Pfizer
ES2162235T3 (es) 1996-01-15 2001-12-16 Janssen Pharmaceutica Nv Piridazinaminas inhibidoras de la angiogenesis.
AU768130B2 (en) 1998-04-09 2003-12-04 Johns Hopkins University School Of Medicine, The Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
AU780358B2 (en) 1999-06-08 2005-03-17 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
NZ530580A (en) * 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
CA2483311A1 (en) 2002-04-22 2003-10-30 Philip A. Beachy Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
CA2564996A1 (en) 2004-05-08 2006-01-12 Taeyoung Yoon 3-aryl-5,6-disubstituted pyridazines
KR20180122750A (ko) 2004-09-02 2018-11-13 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (de) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
DK2137162T3 (en) 2007-03-15 2018-11-26 Novartis Ag Organic compounds and their applications
US8153633B2 (en) * 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
WO2009035568A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
NZ586121A (en) * 2007-12-13 2012-03-30 Siena Biotech Spa Benzimidazole derivatives as hedgehog pathway antagonists and therapeutic applications thereof
CN102066353B (zh) 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2732101C (en) * 2008-08-04 2013-09-17 Amgen Inc. Aurora kinase modulators and methods of use
MX2011004683A (es) 2008-11-03 2011-06-20 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida.
BRPI0921782A2 (pt) 2008-11-17 2019-09-24 Lilly Co Eli antagonistas da via hedgehog de piridazina tetrassubstituída
MX2011005176A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Similar Documents

Publication Publication Date Title
JP2012530705A5 (cg-RX-API-DMAC7.html)
JP2012507535A5 (cg-RX-API-DMAC7.html)
JP2010523692A5 (cg-RX-API-DMAC7.html)
JP2011527666A5 (cg-RX-API-DMAC7.html)
JP2017504611A5 (cg-RX-API-DMAC7.html)
JP2015508749A5 (cg-RX-API-DMAC7.html)
JP2014515013A5 (cg-RX-API-DMAC7.html)
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
JP2014504646A5 (cg-RX-API-DMAC7.html)
JP2009535462A5 (cg-RX-API-DMAC7.html)
JP2014507446A5 (cg-RX-API-DMAC7.html)
JP2014507464A5 (cg-RX-API-DMAC7.html)
JP2010536766A5 (cg-RX-API-DMAC7.html)
JP2015180703A5 (cg-RX-API-DMAC7.html)
JP2013505969A5 (cg-RX-API-DMAC7.html)
JP2014508811A5 (cg-RX-API-DMAC7.html)
JP2013531028A5 (cg-RX-API-DMAC7.html)
JP2011519854A5 (cg-RX-API-DMAC7.html)
JP2012255026A5 (cg-RX-API-DMAC7.html)
IL202018A (en) 4,2-Difluoro-n- {2- (Methylaoxy) -5- [4- (4-Pyridazinyl) -6-Quinolinyl] -3-Pyridinyl} Benzenesulfonamide, its Pharmaceuticals and Its Use in the Treatment of Pi3 Kinase-Related Diseases
JP2011500550A5 (cg-RX-API-DMAC7.html)
JP2013509429A5 (cg-RX-API-DMAC7.html)
JP2013544860A5 (cg-RX-API-DMAC7.html)
JP2014528403A5 (cg-RX-API-DMAC7.html)
JP2015501799A5 (cg-RX-API-DMAC7.html)